AFT Pharmaceuticals - H123 focused on portfolio expansion
AFT reported strong post COVID-19 revenue momentum in H123 (NZ$65.8m, 18.4% y-o-y growth), driven by robust organic growth across all regions,...
814 Views
AFT Pharmaceuticals: A Picture of Health; OUTPERFORM
We initiate full coverage of AFT Pharmaceuticals (AFT) with a 12 month target price of NZ$5.00 and an OUTPERFORM rating; we think the market under...
238 Views
AFT Pharmaceuticals - Further studies for Maxigesic IV’s US nod
AFT Pharmaceuticals announced that, along with partner Hyloris Pharmaceuticals, the company will initiate additional studies to address the FDA...
760 Views
AFT Pharmaceuticals - Collaboration for developing birthmark medicine
AFT Pharmaceuticals has announced a collaboration and in-licensing agreement with Massey Ventures (the commercialisation arm of Massey University,...
796 Views
AFT Pharmaceuticals - Pascomer falls short of FDA mandated threshold
AFT Pharmaceuticals announced that its Pascomer Phase II clinical trial has failed to meet its primary endpoint of a two-point improvement on the...
796 Views